BioTime, Inc. (NYSE MKT:BTX) Q3 2018 Earnings Conference Call Transcript

Nov 08, 2018 • 04:30 pm ET


BioTime, Inc. (NYSE MKT:BTX) Q3 2018 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Welcome to BioTime, Inc.'s Third Quarter 2018 Conference Call. At this time all participants are in a listen-only mode. An audio webcast of this call is available on the investor's section of BioTime's website at This call is subject to copyright property of BioTime, Inc. and recording, reproduction or transmission of this call without expressed written consent of BioTime is strictly prohibited. As a reminder, today's call is being recorded.

I would now like to introduce your host for today's conference, Ioana Hone of BioTime Investor Relations. Ms. Hone, please go ahead.

Ioana Hone

Thank you, Tiffany. Good morning, and thank you for joining us. My name is Ioana Hone, and I am responsible for Investor Relations at BioTime, and it is a pleasure to be with you today. A press release reporting our third quarter 2018 financial results was issued earlier today, November 8th, 2018 and can be found on the Investor Section of our website.

(Forward-Looking Cautionary Statements).

Joining us today are our newly appointed CEO, Brian Culley; our CFO, Russell Skibsted; and our SVP of Clinical and Medical Affairs, Gary Hogge. The executives will provide prepared remarks, then take questions from analysts and institutional holders.

With that, I'd like to turn the call over to Brian Culley, who joined BioTime as its new CEO on September 17th.

Brian M. Culley

Thank you, Ioana, and good morning, everyone. We have a lot of important items to update for you today, so thank you for joining the call. To start off, I'm extremely pleased to have been selected by the BioTime Board of Directors to lead the next phase of our growth. I've joined what I believe is a transformational period for this company. We aim to become the premier cell therapy company, and I believe we have the opportunity to do this by being one of the first cell therapy companies to turn ambitious research ideas into treatment realities.

I want BioTime to lead this mission, and I believe I can help drive the process through my experience building the teams, infrastructure and institutional awareness necessary to advance the pipeline of treatments through clinical development. I also have a successful history of engagement with patients and advocacy groups, which can further increase our visibility and significance with the medical investment communities by ensuring awareness and appreciation of our clinical accomplishments.

Some of you are aware of my background, so I'll just mention briefly that I have more than 25 years of technical and business experience across diverse operational areas, including strategy, finance, product licensing and product development. Early in my career, I worked at the bench, running experiments at both academic and for-profit research laboratories, so I understand the process and the potential of basic research. But I also spent time in the regulatory world and know what it takes to successfully file a new drug application with the FDA.

I have a strong business development background and have bought and sold not only individual drug programs, but also several companies. To give